According to Coherent Market Insights, the global Drug Eluting Stents market is estimated to be valued at $2,897.2 million in 2022 and is expected to exhibit a CAGR of 6.6 % during the forecast period (2022-2030).
December 23, 2022
Global Drug Eluting Stents Market to Surpass US$ 4,844.6 Million by 2030, Says Coherent Market Insights
December 23, 2022 — According to Coherent Market Insights, the global Drug Eluting Stents market is estimated to be…
Read More
The first of its kind study involved 60 patients and confirmed Electroducer Sleeve as a safe and effective treatment for heart diseases
December 23, 2022
Electroducer announces the publication of positive results from its pilot study in EuroIntervention medical journal
December 23, 2022 — Electroducer, a company developing an innovative and cost-effective medical device for the…
Read More
Johnson & Johnson today announced it has completed its acquisition of Abiomed, Inc. Abiomed is now part of Johnson & Johnson and will operate as a standalone business within Johnson & Johnson’s MedTech segment.
December 22, 2022
Johnson & Johnson Completes Acquisition of Abiomed
December 22, 2022 — Johnson & Johnson today announced it has completed its acquisition of Abiomed, Inc. Abiomed is…
Read More
The AcQCross Qx system combines the dilator and needle needed to perform left-atrial appendage closure procedures, eliminating the need to swap equipment mid-surgery while crossing into the left side of the heart. (Pixabay)
December 22, 2022
Acutus Medical Achieves EU MDR Submission Milestone in Sale of Left-Heart Access Portfolio to Medtronic
December 22, 2022 — Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac…
Read More
Collaborative team from Rockefeller University, Cleveland Clinic publish findings in Science
December 22, 2022
Research Identifies Potential Genetic Cause for MIS-C Complication Following COVID-19 Infection
December 22, 2022 — New research findings have revealed an underlying genetic cause for why some children who have had…
Read More
Individuals with coronary artery disease exist on a spectrum of disease, such as the amount of plaque build-up in the arteries of the heart; however, the disease is conventionally classified as broad categories of case (yes disease) or control (no disease), which may result in misdiagnosis. A digital marker for coronary artery disease derived from machine learning and electronic health records can better quantify where an individual falls on the disease spectrum. Credit: Icahn School of Medicine at Mount Si
December 22, 2022
Digital Marker for Coronary Artery Disease Built by Researchers at Mount Sinai
December 22, 2022 — Using machine learning and clinical data from electronic health records, researchers at the Icahn…
Read More
Robbin Cohen, MD, now serves as director of the Cardiac Surgery Program at Huntington Health, a Cedars-Sinai affiliate, and will be practicing out of Huntington Health’s Pasadena campus.
December 21, 2022
Cedars-Sinai Expands Cardiac Surgery at Huntington Health
December 21, 2022 — The Smidt Heart Institute at Cedars-Sinai is again expanding its geographic reach and surgical…
Read More
The Arrhythmia Care Team at Corewell Health Celebrate First Successful Procedures With New Genesis Robotic Cardiac Ablation System from Stereotaxis.
December 21, 2022
Corewell Health Grows Robotic Program to Treat Heart Rhythm Disorders with Adoption of Stereotaxis’ Genesis System
December 21, 2022 — Stereotaxis, a global leader in robotic technologies for the treatment of cardiac arrhythmias,…
Read More
Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint
December 21, 2022
CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology
December 21, 2022 — Esperion announced that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting …
Read More
Arrow International, LLC, a Subsidiary of Teleflex, Inc, recalls Arrow AutoCAT 2, AC3 intra-aortic balloon pumps for unexpectedly short battery run times
December 20, 2022
Teleflex Recalls Arrow Intra-Aortic Balloon Pumps for Short Battery
The U.S. Food and Drug Administration (FDA) has issued a Class I recall on the Arrow AutoCAT 2 and AC3 Intra-Aortic…
Read More
Late-breaking clinical trials for the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.23/WCC) have been announced.
By Melinda Taschetta-Millane
December 20, 2022
ACC 2023 Late-breaking Clinical Trials Announced
Late-breaking clinical trials for the American College of Cardiology’s Annual Scientific Session Together with World…
Read More
Companies initiate research agreement supporting development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosis
December 19, 2022
Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease
December 19, 2022 —  Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has…
Read More
End-to-end platform tailored for the hospital’s vascular care team helps detect suspected vascular disease and improve patient outcomes
December 19, 2022
Delray Medical Center Advances its Endovascular Program as the First Hospital in Florida to Acquire the AI-Powered Viz Vascular Suite
December 19, 2022 —  As a leader in vascular care, Delray Medical Center is the first hospital in Florida to acquire…
Read More
suPAR overexpression leads to increased atherosclerotic and necrotic plaques in a murine model of atherosclerosis. WT (n = 18) and suPARTg (n = 21) mice were maintained on a low-fat diet until 3 months of age and were then transfected with Pcsk9-AAV and fed a western diet (WD) for 10 weeks. At this point, aortic roots were obtained, paraffin embedded, and stained with H&E and Mac2 (galectin 3). (A) Cross sections of aortic roots from C57BL/6 WT and suPARTg mice show total lesion area, outlined in dashed lin
December 16, 2022
New Immune Target to Treat Cardiovascular Disease Discovered
December 16, 2022 —  For the longest time, clinicians have treated cardiovascular disease by focusing on diabetes and…
Read More
From left, Craig Schumacher, Jake and Yvette Honda-Schumacher. Image courtesy of Cedars-Sinai
December 16, 2022
A Heart Fix That Fits
December 16, 2022 —  Yvette Honda-Schumacher was 20 weeks pregnant and had just had a routine anatomy ultrasound when…
Read More
Innovative approach can deliver high-fidelity cardiopulmonary exercise test results comparable to gold-standard testing with a wearable sensor during routine daily activities
December 15, 2022
physIQ’s eVO2Max Demonstrates Breakout Ability to Estimate Cardiopulmonary Functional Capacity from Wearable Sensor Data During Daily Routine Activity
December 15, 2022 — physIQ announced a novel approach to estimating maximum oxygen utilization (VO2Max) using wearable…
Read More
Doctors from the Emory Heart & Vascular Center are joining forces with the Family Heart Foundation, a leading research and advocacy organization, to find and more widely treat undiagnosed patients living with a common genetic condition that causes very high levels of unhealthy cholesterol, heightening the risk for heart attacks and strokes even at a young age.
December 15, 2022
Emory Doctors and Family Heart Foundation Team Up to Help Patients with Dangerously High Cholesterol Caused by Genetic Condition
December 15, 2022 —  Doctors from the Emory Heart & Vascular Center are joining forces with the Family Heart…
Read More
From left, Qian Ma, PhD, and Yuqing Huo, MD, PhD. Photo courtesy of Michael Holahan, Augusta University
December 15, 2022
New Target in the Fight Against Heart Disease
December 15, 2022 —  Soon after cholesterol and fat start depositing on the lining of the blood vessels that supply…
Read More
Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping awareness about the extent and impact of underdiagnosis and undertreatment of aortic stenosis (AS).
December 14, 2022
Edwards Identifies Top Data Releases of 2022 that Highlight the Impacts of Aortic Stenosis Undertreatment
December 14, 2022 — Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping…
Read More
Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping awareness about the extent and impact of underdiagnosis and undertreatment of aortic stenosis (AS).
December 14, 2022
Preventing Millions of Strokes and Heart Attacks Doesn’t Have to Come with the Risk of Life-threatening Bleeding
December 14, 2022 — Verseon announced that the European Journal of Medicinal Chemistry has published a paper describing…
Read More
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now